Clinical Evidence of the Relationship Between Alanine Aminotransferase and Diabetic Kidney Disease
Yaru Bi,Yang Yang,Xiaojie Yuan,Jiping Wang,Zhiyuan Liu,Suyan Tian,Chenglin Sun
DOI: https://doi.org/10.2147/dmso.s442165
2024-01-21
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Yaru Bi, 1, &ast Yang Yang, 2, &ast Xiaojie Yuan, 3 Jiping Wang, 3 Zhiyuan Liu, 4 Suyan Tian, 5 Chenglin Sun 1, 3 1 Department of Endocrinology and Metabolism, First Hospital of Jilin University, Changchun, 130000, People's Republic of China; 2 Department of Health Examination Center, First Hospital of Jilin University, Changchun, 130000, People's Republic of China; 3 Department of Clinical Nutrition, First Hospital of Jilin University, Changchun, 130000, People's Republic of China; 4 Department of Clinical Medicine, Yanbian University, Yanji, 136200, People's Republic of China; 5 Division of Clinical Research, First Hospital of Jilin University, Changchun, 130000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Suyan Tian; Chenglin Sun, Email ; Aim: Multiple studies have investigated the association between alanine aminotransferase (ALT) and diabetes mellitus (DM); however, only a few studies have specifically examined the relationship between ALT and diabetic kidney disease (DKD). This study aimed to investigate the relationship between ALT and DKD using clinical data. Methods: A cross-sectional study was conducted on 668 individuals that included non-DM (N=281), DM without DKD (N=160), and DKD (N=227) patients. A generalized additive model (GAM) was used to examine the dose–response relationship between ALT and DKD risk. We also analyzed the data from the US National Health and Nutrition Examination Survey (NHANES) 2015– 2018 using the same statistical methods; 4481, 1110, and 671 individuals were included in the non-DM, DM without DKD, and DKD groups, respectively. Results: The changes in ALT activity among the non-DM, DM without DKD, and DKD groups showed a similar pattern in both our clinical data and the NHANES dataset. ALT activity increases with the onset of DM, whereas ALT activity decreases when DM progresses to DKD. The GAM revealed a nonlinear U -shaped relationship between ALT and DKD risk in the two datasets, and the lowest range of ALT was 40– 50 IU/L. Both lower ( 50 IU/L) ALT activity were found to be positively associated with DKD risk. Conclusion: A U -shaped nonlinear association between ALT and DKD was found in our clinical data and NHANES data. DKD risk was increased by both lower or higher ALT activity. To confirm the causality of nonlinear relationship, larger prospective studies or Mendelian randomization analysis are required. Keywords: alanine aminotransferase, diabetic kidney disease, dose–response relationship, NHANES Diabetic kidney disease (DKD) is a chronic kidney disease (CKD) associated with diabetes mellitus (DM). Clinically, it is defined as increased albuminuria and/or reduced estimated glomerular filtration rate (eGFR) or both. DKD develops in approximately 40% of patients with DM, 1 making it one of the most frequent complications of DM. It is estimated that the all-cause mortality risk in patients with DKD is approximately 30 times greater than that in diabetic patients without DKD, 2 which poses a great threat to human health. Therefore, it is important to identify the risk factors of DKD for its early prevention and intervention. Alanine aminotransferase (Enzymes Commission number: 2.6.1.2; ALT) is an enzyme that catalyzes the transfer of an amino group from alanine to α-ketoglutarate. 3 It is mainly concentrated in the cytosol of hepatocytes and is also located in other tissues, such as skeletal muscle and myocardial tissue. 3 Several pathological conditions related to the above tissues damage, such as viral hepatitis, alcoholic/nonalcoholic fatty liver disease, and skeletal muscle disease, could lead to elevated serum ALT activity. In addition, recent epidemiological studies have shown that elevated ALT activity is also associated with an increased risk of diabetes. 4–8 For example, one prospective study including 9337 non-diabetes individuals with a medium of 12-year follow-up showed that patients with ALT activity in the highest quartile had a 1.68-fold greater risk of developing DM than did those in the lowest quartile [hazard ratio=1.68, 95% confidence interval (CI)=1.49–1.89] after adjusting for potential confounding factors. 9 A meta-analysis including 17 prospective studies also revealed that ALT (per 1-standard deviation change in log ALT) increased the risk of diabetes (relative risk=1.26, 95% CI=1.14–1.41). 10 Conversely, when diabetes progresses to the DKD stage, its relationship with ALT has been less investigated, and the limited finding -Abstract Truncated-
endocrinology & metabolism